CJC-1295 is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) extensively evaluated in preclinical models for its ability to extend the plasma half-life of secretagogue signaling. This technical guide outlines the molecular mechanism, comparative kinetics, and analytical standards required for evaluating CJC-1295 in laboratory research settings.
CJC-1295 is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) extensively evaluated in preclinical models for its ability to extend the plasma half-life of secretagogue signaling. This technical guide outlines the molecular mechanism, comparative kinetics, and analytical standards required for evaluating CJC-1295 in laboratory research settings.
In biomedical literature, CJC-1295 for research refers to a synthetic 29-amino-acid peptide derivative of endogenous growth-hormone-releasing hormone (GHRH 1-29). It is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. By substituting specific amino acid residues at positions 2, 8, 15, and 27, the peptide gains enhanced enzymatic stability against dipeptidyl peptidase-IV (DPP-IV) cleavage, making it a valuable tool for examining neuroendocrine signaling.
Investigators utilize CJC-1295 for research primarily to assess how prolonged activation of GHRH receptors influences endocrine axes without inducing rapid receptor desensitization. Available in both modified forms—with or without a Drug Affinity Complex (DAC)—this peptide enables precise control over half-life and bioavailability in controlled in vitro and animal experimental models.
Because native GHRH has an extremely short biological half-life (often under 10 minutes in plasma), structural modification is necessary to study sustained endocrine cascades. The tetrasubstituted design of CJC-1295 allows laboratory researchers to isolate long-term trophic signaling from the confounding variables of rapid metabolic degradation.
CJC-1295 operates as a potent agonist at the GHRH receptor (GHRHR), a G-protein coupled receptor predominantly localized on the anterior pituitary somatotropes. Upon ligand binding, the receptor undergoes a conformational change that stimulates the Gs alpha subunit, activating adenylyl cyclase and triggering an intracellular accumulation of cyclic adenosine monophosphate (cAMP).
This elevation in cAMP activates protein kinase A (PKA), which subsequently phosphorylates specific transcription factors, such as CREB. In vitro assays demonstrate that this signaling cascade upregulates endogenous growth hormone transcription while stimulating the exocytosis of stored GH granules. Preclinical models indicate that this physiological mechanism preserves the natural pulsatile pathway of endocrine release, avoiding the abrupt, non-physiological spikes associated with exogenously administered recombinant growth hormone.
Furthermore, GHRH receptor signaling modulates downstream gene networks responsible for cellular proliferation, protein synthesis, and extracellular matrix remodeling. By serving as a selective GHRHR ligand, CJC-1295 provides researchers with a targeted chemical probe for evaluating pituitary feedback loops and secretagogue interactions across diverse experimental models.
A critical distinction in secretagogue literature centers on the presence of the Drug Affinity Complex (DAC). When synthesized with the DAC moiety (a reactive maleimido derivative attached to the C-terminal lysine), CJC-1295 DAC covalently binds to circulating serum albumin following systemic administration in animal models. This bioconjugation shields the peptide from renal clearance and proteolysis, extending its terminal half-life to several days.
Conversely, the free peptide variant—often designated as Modified GRF 1-29 or CJC-1295 without DAC—lacks this covalent reactive group. While retaining the tetrasubstituted amino acid modifications that resist DPP-IV cleavage, its plasma half-life is measured in minutes to hours rather than days. This distinction allows investigators to choose between sustained basal elevation and transient, acute secretory spikes.
Selecting between these two formulations depends on the experimental protocol. In vitro cell cultures typically employ Modified GRF 1-29 due to the absence of circulating serum albumin, whereas long-term animal studies investigating steady-state serum IGF-1 levels often utilize the DAC-conjugated variant to minimize handling stress and injection frequency.
In vivo rodent models demonstrate that CJC-1295 administration results in dose-dependent elevations in both growth hormone and insulin-like growth factor 1 (IGF-1). Unlike exogenous GH administration, which can suppress endogenous somatotrope activity through negative feedback, GHRH analogs maintain the pituitary gland's sensitivity to natural inhibitory signals like somatostatin.
Data from preclinical literature indicate that CJC-1295 preserves normal GH pulsatility while elevating basal growth hormone levels. This produces a steady, proportional increase in circulating IGF-1 derived primarily from hepatic synthesis. The resulting systemic increase in IGF-1 mediates many of the downstream physiological effects observed in preclinical research protocols.
Researchers analyzing serum biochemistry in animal models consistently report sustained IGF-1 elevation following single or repeated exposures to CJC-1295. These kinetics render the compound particularly useful for examining long-term gene expression shifts, skeletal muscle hypertrophy pathways, and cellular senescence markers in controlled laboratory settings.
The primary focus of empirical inquiry involving CJC-1295 centers on its downstream effects on cellular repair mechanisms and substrate metabolism. In animal models of tissue injury, elevated IGF-1 signaling secondary to GHRH receptor stimulation enhances satellite cell activation, facilitating myoblast proliferation and skeletal muscle fiber regeneration.
Additionally, preclinical studies suggest that sustained GHRH activation shifts metabolic substrate utilization toward lipolysis. By upregulating hormone-sensitive lipase activity in adipose tissue models, CJC-1295 exposure aids in reducing visceral lipid accumulation while maintaining lean tissue mass during catabolic stress protocols.
Investigational models of connective tissue healing also demonstrate increased collagen transcription and extracellular matrix deposition following GHRH analog exposure. These findings have led to expanded research into tendon, ligament, and articular cartilage repair pathways within the broader field of growth hormone secretagogues.
In scientific literature, CJC-1295 is frequently evaluated alongside growth hormone secretagogue receptor (GHSR) agonists, commonly referred to as growth hormone-releasing peptides (GHRPs). Because GHRH agonists and GHRPs act via distinct receptor pathways—GHRHR and GHSR (ghrelin receptor), respectively—co-administration results in a synergistic release of growth hormone.
Experimental assays demonstrate that combining CJC-1295 with a selective GHRP such as Ipamorelin produces a amplified secretory response compared to either compound administered in isolation. This synergy occurs because GHSR activation suppresses endogenous somatostatin release at the hypothalamic level while simultaneously enhancing intracellular calcium influx within somatotropes, allowing GHRH-mediated cAMP signaling to exert maximum effect.
Laboratory protocols investigating maximum physiological pituitary output often utilize combination regimens to examine ceiling effects, receptor crosstalk, and signal amplification pathways. Such studies provide critical insight into dual-receptor regulation within neuroendocrine tissue matrices.
To contextualize CJC-1295 within the landscape of peptide research, investigators frequently compare its structural stability, half-life, and target specificity against related secretagogues. The table and comparative analysis below illustrate key differences among prominent GHRH analogs and GH secretagogues evaluated in laboratory literature.
While Sermorelin shares the baseline native GHRH 1-29 sequence, it lacks the four substituted amino acids that protect CJC-1295 from rapid DPP-IV enzymatic cleavage. Consequently, Sermorelin exhibits a significantly shorter half-life in plasma. On the other hand, Tesamorelin incorporates a hexenoyl group attached to the N-terminal trans-3-hexenoic acid, providing high specificity for lipolytic research models but differing structurally from the tetrasubstituted design of CJC-1295.
Unlike these GHRH analogs, Ipamorelin targets the ghrelin receptor rather than the GHRH receptor. Comparing these compounds within a single experimental framework allows researchers to isolate GHRH-specific signaling from ghrelin-mediated pathways, establishing clear baseline data for metabolic and tissue-repair investigations. For broader contextual data, researchers can review our analytical peptide research hub.
Achieving reproducible experimental outcomes with CJC-1295 requires strict adherence to laboratory handling protocols. Lyophilized research peptides are sensitive to ambient temperature fluctuations, light exposure, and mechanical agitation. Upon receipt, lyophilized vials should be stored in a controlled freezer environment at -20°C or -80°C for long-term stability.
Reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile laboratory-grade water, depending on the immediate requirements of the assay protocol. The diluent should be introduced slowly down the interior glass wall of the vial to prevent turbulent splashing, which can denature the peptide's secondary structure. Gentle swirl agitation—never vortexing—is recommended to complete solubilization.
Once reconstituted, aqueous solutions of CJC-1295 should be stored at 2°C to 8°C and used within an established experimental window to prevent hydrolytic degradation. For prolonged in vitro studies requiring serial dilutions, aliquoting the stock solution into single-use cryogenic vials prior to freezing helps avoid destructive freeze-thaw cycles.
Experimental integrity relies entirely on the chemical purity and structural identity of the research reagents used. Substandard or contaminated peptides introduce unquantifiable variables that invalidate cell culture viability and animal bioassays. PX1 Research subjects every batch of CJC-1295 to rigorous analytical testing in ISO 17025 accredited facilities.
Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring that the primary peptide peak represents ≥98% of the total UV absorbance chromatogram. Molecular weight and sequence identity are confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS), matching the observed mass-to-charge ratio against theoretical molecular weight calculations.
Furthermore, because bacterial endotoxins can induce severe inflammatory cascades in biological assays, PX1 Research conducts quantitative Chromogenic LAL (Limulus Amebocyte Lysate) testing on every lot. Guaranteeing endotoxin levels below 0.01 EU/mg ensures that cellular responses observed during experiments stem strictly from GHRH receptor agonism rather than lipopolysaccharide (LPS) contamination.
High-throughput research facilities and academic institutions require full supply chain visibility and lot-to-lot consistency. PX1 Research manufactures all compounds within GMP-compliant facilities located in the United States, adhering to stringent quality management protocols from initial solid-phase peptide synthesis (SPPS) through final lyophilization.
Every vial shipped from our distribution centers in California and Arizona is linked to a lot-specific Certificate of Analysis (COA). Principal investigators can verify HPLC chromatograms, mass spectra, and endotoxin reports prior to initiating experimental procedures. This level of analytical transparency ensures compliance with internal laboratory quality control guidelines.
Whether procuring standard analytical quantities from our comprehensive catalog of research peptides or setting up bulk institutional supply via bulk laboratory accounts, PX1 Research provides the structural reliability, analytical documentation, and fast domestic fulfillment necessary to support continuous scientific discovery.
What is the primary mechanism of CJC-1295 in preclinical research?
CJC-1295 acts as a synthetic agonist at the GHRH receptor on anterior pituitary somatotropes. It stimulates adenylyl cyclase, raising intracellular cAMP levels and triggering the physiological synthesis and pulsatile secretion of endogenous growth hormone and downstream IGF-1.
What is the difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a Drug Affinity Complex that covalently binds to circulating serum albumin, extending its biological half-life to several days in animal models. CJC-1295 No DAC (Modified GRF 1-29) lacks this complex, resulting in a significantly shorter half-life measured in minutes to hours.
How should CJC-1295 be reconstituted for laboratory use?
CJC-1295 should be reconstituted by slowly directing a sterile diluent, such as Bacteriostatic Water or sterile saline, down the side of the vial wall. The vial should be gently swirled until fully dissolved. Avoid vigorous shaking or vortexing to prevent peptide denaturization.
What purity level is required for CJC-1295 research applications?
High-purity laboratory research requires CJC-1295 verified at ≥98% purity by RP-HPLC, with structural identity confirmed by Mass Spectrometry (MS). Low endotoxin levels (<0.01 EU/mg) are critical to avoid confounding immune responses in in vitro and in vivo assays.
How is CJC-1295 stored to maintain long-term chemical stability?
Lyophilized CJC-1295 should be stored in a desiccated environment at -20°C or -80°C away from light. Once reconstituted, stock solutions should be kept refrigerated at 2°C to 8°C and used within established laboratory stability windows, avoiding repeated freeze-thaw cycles.
Why is CJC-1295 often studied in combination with Ipamorelin?
CJC-1295 stimulates the GHRH receptor while Ipamorelin targets the GHSR (ghrelin) receptor. Co-administration in preclinical research yields a synergistic elevation of growth hormone release by activating distinct signaling cascades and suppressing somatostatin inhibition simultaneously.
Where does PX1 Research source and manufacture its CJC-1295?
PX1 Research manufactures its peptides in GMP-compliant facilities in the United States. Orders ship directly from fulfillment centers in California and Arizona, complete with lot-specific third-party COAs from ISO 17025 accredited testing laboratories.
Can CJC-1295 be used for medical or therapeutic purposes?
No. CJC-1295 supplied by PX1 Research is strictly designated for laboratory research use only (RUO). It is not intended for human or animal therapeutic, diagnostic, or clinical application.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.